Request Demo

Last update 17 Mar 2026

Oxycodone Hydrochloride

Last update 17 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Oxycodone hydrochloride (USP), Oxycodone Hydrochloride Hydrate, ATLP-02

+ [32]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainChronic PainPain

Inactive Indication

Acute PainAnalgesiaLow Back Pain+ [1]

Originator Organization

Roxane Laboratories, Inc.

Active Organization

SpecGx LLC

Purdue Pharma LP

Beijing Wellso Pharmaceutical Co., Ltd.

+ [3]

Inactive Organization

Bard Pharmaceuticals Ltd.Egalet Ltd.

Beijing Mengdi Pharmaceutical Co. Ltd.

+ [4]

License Organization

Protega Pharmaceuticals, LLC.

Inspirion Delivery Sciences LLC

Daiichi Sankyo, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (26 Oct 1998),

Pain

Regulation-

Structure/Sequence

Molecular FormulaC18H22ClNO4

InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N

CAS Registry124-90-3

615

Clinical Trials associated with Oxycodone Hydrochloride

NCT05265052

/ Not yet recruitingPhase 2

A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Start Date01 Dec 2026

Sponsor / Collaborator

Aitisi Biotechnology (Shanghai) Co. Ltd.

ChiCTR2600119589

/ Not yet recruitingNot ApplicableIIT

A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China

Start Date01 Jun 2026

Sponsor / Collaborator

Zhejiang Cancer Hospital

ChiCTR2600119394

/ Not yet recruitingNot ApplicableIIT

Analgesic Efficacy of Oxycodone Combined with Bilateral Modified Thoracoabdominal Nerves Block through Perichondrial Approach (M-TAPA) for Laparoscopic Radical Gastrectomy

Start Date01 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Oxycodone Hydrochloride

100 Translational Medicine associated with Oxycodone Hydrochloride

100 Patents (Medical) associated with Oxycodone Hydrochloride

3,728

Literatures (Medical) associated with Oxycodone Hydrochloride

01 Apr 2026·WATER RESEARCH

Ice-covered lakes, hidden threats: Seasonal fate and risks of antibiotics and PAHs

Article

Author: Liu, Xuemei ; Jiang, Lili ; Zhang, Guangxin ; Ju, Hanyu ; Zhang, Jingjie ; de Goede, Erik ; Wang, Peixin ; Li, Jie

In cold-region lakes, the spatiotemporal dynamics of pollutants are controlled by complex and interacting physical, chemical, and biological processes, necessitating systematic quantitative assessment. However, this field has received less than 2% of total research attention in the freshwater literature, revealing a substantial knowledge gap. Moreover, different classes of emerging contaminants often display distinct risk patterns within the same aquatic ecosystem. To address this gap, we investigated Chagan Lake -a representative ice-covered lake in Northeast China-using antibiotics and polycyclic aromatic hydrocarbons (PAHs) as typical case pollutants. A seasonally coupled hydrodynamic-pollutant fate model was developed to simulate the full annual cycle of ice formation, coverage, thawing, and melting, with oxytetracycline (OXY) and naphthalene (NAP) selected as representative compounds. The model was rigorously calibrated and validated against 2021 field observations, achieving Kling-Gupta efficiency (KGE) values above 0.50 for pollutant concentrations, indicating robust predictive capability. Scenario analyses were then conducted: (1) water diversion altered hydrodynamic regimes and promoted long-term pollutant attenuation; (2) external load reduction combined with sediment dredging produced cross-seasonal "source-sink" regulation; and (3) NAP exhibited a threshold-type response, with risks sharply increasing once external inputs surpassed sediment buffering capacity. Comparative analysis indicated that OXY consistently posed ecological risk, whereas risks associated with NAP generally remained low except under threshold exceedance scenarios. These findings highlight the interplay between contaminant properties and seasonal hydrological processes, providing a transferable framework for pollution control and risk prevention in ice-affected lake ecosystems.

01 Mar 2026·BRAIN RESEARCH BULLETIN

HSP47 inhibitor Col003 inhibits glial scar formation and improves neurological function in ischemic stroke in rats

Article

Author: Zhou, Kejian ; Liang, Tingting ; Li, Jinpin ; Xie, Xiaoyun ; Xie, Yuliang ; Liu, Jingli ; Li, Haoying

BACKGROUND:

Glial scarring is a major obstacle for axonal regeneration and neural repair in the late stage of ischemic stroke. Reactive astrocytes are the main component of the glial scar. Heat shock protein 47 (HSP47) is significantly expressed in reactive astrocytes and remains present in the glial scar. However, the role of HSP47 in glial scar formation in ischemic stroke remains unclear.

METHODS:

HSP47 was identified in the peri-infarct region of rats at 1, 7, and 14 days post middle cerebral artery occlusion (MCAO). The rats received daily tail vein injections of the HSP47 inhibitor Col003 from days 1-14 following MCAO. Glial scar, brain atrophy volume, neurological score was detected after ischemia.

RESULTS:

HSP47 levels were increased in the peri-infarct area at 1, 7, and 14 days post-MCAO, as did those in astrocytes subjected to oxygenglucose deprivation/reoxygenation (OGD/R). The HSP47 inhibitor Col003 enhanced neurological functional recovery and minimized glial scar formation. Col003 inhibited the proliferation and migration of OGD/R-induced astrocytes and reduced the expression of glial fibrillary acidic protein, neurocan, and phosphacan. RNA-seq analysis revealed that differentially expressed genes in the Col003 treatment group were enriched in the JAK2/STAT3 pathway, which is associated with astrogliosis and glial scar formation.

CONCLUSION:

Our findings demonstrated that Col003 inhibited JAK2/STAT3 phosphorylation in OGD/R-induced astrocytes. The HSP47 inhibitor Col003 might suppress astrocyte proliferation, migration, and glial scar formation through the JAK2/STAT3 pathway following ischemic stroke, which suggests a novel therapeutic strategy for the chronic phase of ischemic stroke.

03 Feb 2026·ANALYTICAL CHEMISTRY

Ultrasensitive Tracking of Dual Antiparasitics in Living Tissues: UPLC-MS/MS Reveals Synergistic Distribution of Oxyclozanide and Levamisole Hydrochloride

Article

Author: Zhou, Yaxin ; Li, Haiquan ; Dai, Guonian ; Li, Bing ; Xu, Jing ; Zhou, Xuzheng ; Zhang, Jiyu ; Sun, Kairui ; Wang, Qing

This study addresses the critical gap in tissue distribution kinetics of veterinary anthelmintic combination therapies by developing a novel dual-mode dynamic-switching ultraperformance liquid chromatography coupled with triple quadrupole tandem mass spectrometry (UPLC-MS/MS) method with ultrahigh sensitivity (limit of detection, LOD = 0.5 ng/g). The method enables synchronous quantification of oxyclozanide (OXY, logP = 5.69) and levamisole hydrochloride (LEV, logP = 2.32) in complex biological matrices through optimized ESI+/ESI- ionization and antiadsorption chromatographic separation (BEH C18 column). Validated per VICH GL49 and EMA/ICH guidelines, the assay demonstrated excellent linearity (2-800 ng/g, R² > 0.990), precision (relative standard deviation, RSD ≤ 10.32%), and recovery (91.41-102.49%) across nine tissues. Spatiotemporal profiling in rats revealed distinct pharmacokinetic synergies: OXY exhibited prolonged gastric retention (maximum concentration, C_max = 5377 ng/g, half-life, t_1/2 = 32-48 h) and fecal-dominated excretion (94.58%), while LEV achieved systemic distribution with blood-brain barrier penetration (brain C_max = 501 ng/g) and renal clearance (57.88%). The three-dimensional complementarity (spatial targeting, temporal kinetics, and clearance pathways) provides a mechanistic basis for enhanced anthelmintic efficacy and informs the optimization of withdrawal periods. This work establishes a paradigm for the preclinical evaluation of veterinary drug combinations.

237

News (Medical) associated with Oxycodone Hydrochloride

09 Mar 2026

·www.biospace.com

Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate pain In both ALLEVIATE trials cebranopadol demonstrates significant and sustained pain reduction with a differentiated safety pro abdominoplasty and bunionectomy Human abuse-potential studies showing cebranopadol is l ess abusable than oxycodone and tramadol, further support its potential to offer strong pain relief with an improved safety profile MONMOUTH JUNCTION, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced debut data from its Phase 3 ALLEVIATE-1 and ALLEVIATE-2 studies evaluating the safety and efficacy of cebranopadol, an investigational therapy, for the treatment of moderate-to-severe acute pain in patients following abdominoplasty and bunionectomy surgery, respectively, at the American Academy of Pain Medicine (AAPM) 2026 PainConnect annual meeting. The debut abstract titled, “Results of ALLEVIATE-1 and ALLEVIATE-2 Phase 3 Trials of Cebranopadol, a First-in-Class, Dual NOP/MOP Receptor Agonist for the Treatment of Acute Pain After Abdominoplasty and Bunionectomy,” was presented by Dr. Todd Bertoch, MD, Chief Medical Officer of CenExel Clinical Research, and Principal Investigator on ALLEVIATE-2. “As pain specialists, we often see how inadequately controlled acute pain can linger long after surgery or injury,” said Dr. Todd Bertoch. “If we don’t get ahead of severe pain early, it can become chronic and much harder to treat. These Phase 3 results underscore the potential of cebranopadol to redefine the standard of care for acute pain management.” Cebranopadol is an investigational, first-in-class dual nociceptin/orphanin FQ peptide (NOP) and μ-opioid peptide (MOP) receptor agonist (dual-NMR agonist). By simultaneously activating both receptors, cebranopadol is designed to provide potent analgesia while potentially mitigating many of the risks traditionally associated with preferential MOP agonists. ALLEVIATE-1 clinical trial ( NCT06545097 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study. It enrolled 303 patients undergoing abdominoplasty surgery without liposuction or other collateral procedures across four U.S. sites. Eligible participants were randomized in a 1:1:1 ratio to cebranopadol 400 µg on Days 1 and 2, cebranopadol 400 µg on Day 1 and 200 µg on Day 2 or placebo all administered once daily. The first dose was administered approximately 1 hour prior to abdominoplasty and the second dose approximately 24 hours later. ALLEVIATE-2 clinical trial ( NCT06423703 ) is a Phase 3 multicenter, randomized, double-blind, placebo-and active controlled study. It enrolled 242 patients undergoing unilateral bunionectomy with first metatarsal osteotomy across ten U.S. sites. Eligible participants were randomized in a 1:1:1 ratio to a cebranopadol 400 µg, oxycodone immediate release (IR) 10 mg or placebo. Cebranopadol was administered once daily on Days 1, 2, and 3; placebo was administered at 6, 12, and 18 hours to maintain blinding. Oxycodone 10 mg and placebo were administered every 6 hours. Baseline Demographics and Allocation: In the abdominoplasty study, 303 participants were randomized to treatment at four sites in the U.S., and 292 (96.4%) completed the study. Eleven participants discontinued the study due to adverse events (AEs) (3), lost to follow-up (2), withdrawal of consent (3), and other (3). In the bunionectomy study, 242 participants were enrolled at 10 locations in the Unites States, and 236 (97.5%) completed the study. One participant was discontinued in the oxycodone group for hypersensitivity, which was considered a severe and serious AE. No other participants discontinued or experienced a severe or serious AE. Across the two trials, baseline characteristics were similar among groups. More participants in the abdominoplasty study had a history of substance abuse. Efficacy and Safety Results The primary endpoints in both trials were met, demonstrating an acceptable benefit-risk pro cebranopadol for the treatment of acute pain following abdominoplasty and bunionectomy: In ALLEVIATE-1, the average total pain score area under the curve (AUC 4-48) for patients dosed with 400 µg cebranopadol was significantly less than placebo (LS mean difference 59.2; SE 10.14; p<0.001). In ALLEVIATE-2, the average total pain score area under the curve (AUC 2-48) for patients dosed with cebranopadol was significantly less than placebo (LS mean difference 56.1; SE 13.49; p<0.001) Following abdominoplasty, a significantly greater proportion of patients receiving cebranopadol 400 µg required no opioid rescue medication compared with those receiving placebo (34.7% vs 9.9%; p<0.001). Following bunionectomy, a significantly higher proportion of patients receiving cebranopadol 400 µg required no opioid rescue medication compared with those receiving placebo (57.5% vs 28.4%; p=0.006) Cebranopadol was generally well tolerated and exhibited a favorable safety profile. Nausea was the most common AE across study groups with exception of placebo group in the bunionectomy study. Other AEs included vomiting, constipation, headache, dizziness, hypertension and pruritus. Ketan Mehta, founder and CEO at Tris Pharma added, “Acute postoperative pain remains a significant clinical challenge, and the standard of care has serious associated risks. With our first-in-class dual NOP/MOP receptor agonist, we are taking a fundamentally new approach to pain relief, one that simultaneously targets two distinct pathways of pain modulation to deliver meaningful pain relief with a reduced risk of side effects associated with preferential MOP agonists. These data validate this mechanism of action and reinforce the potential of cebranopadol to address a critical need for safe and effective treatment options.” About Acute Pain Approximately 80 million adults in the U.S. are treated for acute pain every year 1,2 . Acute pain can be caused by injury, invasive surgery, illness, major trauma and burns. It can last up to three months and typically resolves once the underlying cause is treated or healed. Moderate-to-severe acute pain can often only be effectively treated with opioid analgesics, which, while effective, are associated with risks including respiratory depression, tolerance, dependence, misuse, and overdose. However, undertreating severe pain in the immediate period after onset can increase the risk of a patient developing chronic pain 3,4 . About Cebranopadol Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors (a dual-NMR agonist), for the treatment of moderate-to-severe pain, as well as opioid use disorder (OUD). These receptors are partially homologous to each other, and they play both complementary and distinct roles to modulate pain biology pathways. Studied in over 33 clinical trials in more than 2,200 subjects, cebranopadol’s pro been well characterized in pain management studies. It has demonstrated positive clinical results in acute pain, chronic pain, and diabetic neuropathic pain with a favorable safety profile. The FDA granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it could become the first dual-NMR pain-relief therapy with the potential to provide efficacy equivalent to selective MOP agonists such as oxycodone with less risk of misuse or physical dependence, addiction or overdose.  Cebranopadol’s novel mechanism of action has potential in treating patients with substance use disorders (SUDs). Tris plans to continue to evaluate cebranopadol’s potential to help patients break the cycle of opioid addiction.  The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Tris a five-year grant of up to $16.6 million to study cebranopadol’s potential to treat OUDs and SUDs.  About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction and disorders of the central nervous system. Tris markets a portfolio of best-in-class ADHD products and is developing a promising pipeline of differentiated near-term drug candidates. More information is available at  and on LinkedIn  @TrisPharma .  Media Contact Jonathan Pappas  LifeSci Communication  jpappas@lifescicomms.com Company Contact Cheryl Patnick  Tris Pharma, Inc.  cpatnick@trispharma.com ________________________ Banerjee S, Argaez C. Multidisciplinary Treatment Programs for Patients with Acute or Subacute Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Canadian Agency for Drugs and Technologies in Health. 2019 May 7; PMID: 31498579 Lopez A, Menzie AM, Kenderes M, Rubin JL. A real-world database analysis of the prevalence of pain medication use in the United States. PAIN Reports. 2026 February; DOI: 10.1097/PR9.0000000000001396 McGreevy K, Bottros MM, Raja SN. Preventing Chronic Pain following Acute Pain: Risk Factors, Preventive Strategies, and their Efficacy. European Journal of Pain Supplements. 2012 Nov 11; PMID: 22102847 Sinatra, R. (2010). “Causes and Consequences of Inadequate Management of Acute Pain.” Pain Medicine, 11(12), 1859–1871. doi:10.1111/j.1526-4637.2010.00983.x

Phase 3Clinical ResultFast Track

26 Feb 2026

·www.biospace.com

Opinion: New Painkillers Critical To Fight Opioid Epidemic, Broader Pain Crisis

iStock, tadamichi Alternatives to opioids are desperately needed to better treat moderate to severe acute pain, but to date, we’ve seen few novel analgesics hit the market. In the landscape of modern medicine, pain management stands as a stark outlier. Outside of Vertex Pharmaceuticals’ recently approved Journavx, remedies for pain remain mired in antiquity as fields like oncology and cardiology have embraced groundbreaking immunotherapies, precision medicines and gene therapies. Even opioids, now infamous for an epidemic of misuse, have been marketed for decades, and their core mechanism is unchanged from the opium used in Egypt and India more than three thousand years ago. This needs to change—both to help curb the opioid crisis and to meet the needs of the millions of patients suffering in pain. Often opioids are the only effective treatment for moderate to severe pain, yet they fuel a public health disaster. Even short-term use of opioids for acute pain during post-surgical recovery carries addiction potential. In 2023, nearly 80,000 Americans died of drug overdoses involving opioids, and most were patients first exposed to the drugs via legitimate prescriptions for pain. This well-publicized crisis of addiction and overdoses overshadows another, less visible one, compounding the urgency for new solutions. Namely, due to the risks of opioids, more and more healthcare professionals and patients are declining to use them, leaving acute pain significantly undertreated in many situations. In the U.S., opioids are prescribed in just 15%–20% of acute pain cases. As executives in this notoriously challenging therapeutic area, we are no strangers to the rigor and resilience it takes to develop and bring to market effective and safe pain therapies. Beyond our professional work at Tris Pharma is the personal side of our purpose. We’ve directly witnessed the human impact of untreated pain and opioid addiction, and we feel compelled to help find new solutions. A Field Frozen in Time Pain management lags far behind other therapeutic areas in terms of innovation. In cardiology, statins transformed cholesterol management in the 1980s, followed by PCSK9 inhibitors in the 2010s. Oncology has surged this century with checkpoint inhibitors, CAR T therapies and bispecific antibodies. As a result, deaths from cancer and heart disease have plummeted, and we have changed once-deadly diagnoses into chronic conditions. Cancer Reframing Multiple Myeloma: From Fatal to Chronic and Even Curable Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each patient’s needs. January 21, 2025 · 8 min read · Kate Goodwin Read more By contrast, pain’s toolkit is ancient. Aspirin has been used for millennia and was first marketed as a standardized product in 1899. Lidocaine was first produced in the 1940s, acetaminophen became available in 1950 and nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen have been around since the 1960s. For severe pain, opioids reign supreme. Morphine was isolated in 1803, then more than 100 years later, oxycodone hit the market. Today, dozens of prescription opioids have been approved by the FDA for pain management. But these, of course, come with enormous risk. In 2023, 80% of the 80,000 Americans who died of drug overdoses involving opioids had taken illicit drugs like heroin or fentanyl, but research shows that the majority of these people were first exposed to opioids for pain and ~80% used prescription drugs before trying illicit options. Physicians, wary of lawsuits, regulatory scrutiny and addiction and overdose statistics, increasingly avoid prescribing opioids. Patients, influenced not only by media coverage but also by firsthand experience watching loved ones fall victim to the crisis, often refuse even a single dose after major surgeries like knee replacements or cesareans, opting instead for inadequate treatments and suffering in silence. Without effective alternatives for moderate to severe pain, a void is created in which patients’ pain is not effectively managed. That has long-term consequences for patients that go far beyond their immediate comfort. Research shows that undertreated acute pain can become chronic after the injury has healed due to neuronal rewiring. Some studies, including by myself and my colleagues , suggest ineffective pain control in the days following surgery more than doubles chronic pain risk. As of 2021, chronic pain affected 51.6 million U.S. adults—one-fifth of the population—with 17.1 million experiencing impairment of daily life as a result. The economic cost of chronic pain exceeds $600 billion annually in healthcare and lost productivity—a burden that can be prevented with better treatment of acute pain. We thus urgently need acute pain treatments that patients and physicians trust—ones that are effective, non-addictive and free from overdose risk. Why, then, has the industry not delivered? The scarcity of new pain drugs isn’t due to a lack of effort but rather the problem’s inherent complexity. Pain involves diverse pathways—nociceptive, neuropathic, inflammatory—and lacks clear biomarkers for drug development. This complexity has led to repeated failures: from 2000 to 2020, countless candidates faltered in late-stage trials. A 2023 Biotechnology Industry Organization (BIO) study reported a 0.7% success rate for pain drugs reaching FDA approval, among the lowest in medicine. These failures eroded confidence, prompting a funding retreat. By the 2010s, major pharmaceutical companies like Pfizer and AstraZeneca closed pain research divisions, citing high risks and low returns. Venture capital followed suit, diverting funds to more predictable fields like oncology. Federal support has also been meager; the National Institutes of Health allocates a fraction of the amount to pain research that it devotes to cancer or heart disease, despite pain’s prevalence. This created a vicious cycle: reduced funding stifled innovation, further justifying the pullback. Add to that an opioid crisis that intensified scrutiny on pain drugs and made regulatory hurdles steeper, and investment became even less appealing. A New Dawn Despite these challenges, recent breakthroughs signal hope. A few determined companies have targeted novel mechanisms like voltage-gated sodium channels (NaV1.8), which transmit pain signals without affecting reward pathways, avoiding addiction risks. Vertex led with suzetrigine (Journavx), an oral NaV1.8 inhibitor approved by the FDA in January 2025 for moderate to severe acute pain—the first novel pain drug in decades. Editorial FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment If the attention generated by BioSpace ’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid epidemic. February 7, 2025 · 3 min read · Heather McKenzie Others are advancing. Latigo Biotherapeutics, launched in February 2024 with $135 million, reported positive Phase I data for its NaV1.8 blocker LTG-001 in August 2024. SiteOne Therapeutics, whose lead candidate is the NaV1.8 inhibitor STC-004, was acquired by Eli Lilly in May 2025 in a deal that could be worth up to $1 billion, reflecting improved industry confidence. Our company, Tris Pharma, has progressed through Phase III development with a first-in-class dual NMR agonist (NOP/MOP receptor agonist), which applies an alternative to the traditional mu mechanism utilized by drugs such as morphine, oxycodone and fentanyl. In this new mechanism, both the NOP and MOP receptors add to the pain relief, but also interact with cellular signaling to ameliorate the negative effects of the mu receptor. These developments are reshaping perspectives. Big Pharma is re-entering the space and venture capital is moderately flowing, with pain startups raising hundreds of millions in the last two years. The FDA’s fast-tracking of non-opioid pain candidates further signals regulatory support, addressing the urgent need for alternatives. To dismantle the opioid paradigm, this momentum must endure. New drugs must be clinically successful and be accepted by healthcare providers, insurers and patients, or else the current crises will continue unchanged. Real-world evidence showing fewer addiction cases, overdose fatalities and emergency room visits could spur further investment. Regulatory incentives, like expedited reviews or guaranteed periods of market exclusivity, are vital, as is increased federal funding for pain research. The stakes are immense. Acute pain that can only be effectively treated with opioids affects an estimated 40 million American adults every year and is expected to grow in prevalence with an aging population. Novel mechanisms offer a potential solution: robust pain relief without addiction’s shadow. By fostering research, investment and adoption, we can transform pain management from a relic of ancient medicine into a triumph of modern science, addressing both the visible and hidden opioid epidemics.

Drug ApprovalPhase 3Phase 1AcquisitionClinical Result

25 Feb 2026

·www.biospace.com

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

Vancouver, British Columbia--(News - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs in pain management. The Canadian patent application is directed novel cyclized peptides that are analogues of dynorphin, an endogenous opioid peptide. These compounds are designed to deliver effective pain relief while potentially reducing the adverse effects commonly associated with traditional opioid therapies, such as dependence and tolerance. The invention also encompasses pharmaceutical compositions and methods of use for treating or preventing pain in subjects, reinforcing the therapeutic potential of this technology. This patent application is jointly owned by PreveCeutical Medical Inc. and The University of Queensland, reflecting the strength of the collaborative research partnership between the two organizations. Grant of the application is expected in Q2 2026 - the granted patent will provide exclusivity in Canada until January 2040, subject to maintenance, and forms part of a broader patent family with corresponding applications pending in the United States, Europe, and Australia. This global strategy ensures robust protection for PreveCeutical's intellectual property portfolio and supports its long-term commercialization objectives. PreveCeutical's pain therapy program focuses on developing next-generation peptide-based analgesics that aim to overcome the limitations of conventional opioids. By leveraging advanced peptide engineering and cyclization techniques, these candidates are designed to exhibit enhanced stability and receptor selectivity, which could significantly improve patient outcomes in managing acute and chronic pain. PreveCeutical's CEO, Stephen Van Deventer, commented: "The approval of this application is a significant milestone for PreveCeutical, reaffirming our commitment to pioneering next-generation solutions in pain management. This intellectual property bolsters our position in a global market demanding safer alternatives to opioids and supports our long-term path to commercialization." Further details on the patent can be accessed through the Canadian Patent Search at . About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@preveceutical.com Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at . Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. To view the source version of this press release, please visit

100 Deals associated with Oxycodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00847	Oxycodone Hydrochloride	N02AA05	DBSALT000277

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Shionogi Pharma Co., Ltd.	01 May 2012
Acute Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Chronic Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Pain	United States	Roxane Laboratories, Inc.	26 Oct 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	United States	Egalet Ltd.	01 Mar 2016
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Analgesia	Phase 1	United States	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Australia	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Finland	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	New Zealand	Purdue Pharma LP	01 Jul 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	uksixpgzqn(bawtlkgbzu) = ybprriqdik llpbuxvnjn (xoqfxqpylx, nszaddhfkj - mtrjclszyd) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	uksixpgzqn(bawtlkgbzu) = spbqwyzgjj llpbuxvnjn (xoqfxqpylx, edjzlccyjv - oqkriopmxg) View more
NCT01458015 (CTgov)	Phase 4	Neuralgia	3	oxycodone+tapentadol (Oxycodone)	tbfunhjrql(twzputzchj) = qwvarptafn vdtzzoflnh (ldggzndfjp, wutinkulwz - dfqibyhpfq) View more	-	17 Dec 2024
				oxycodone+tapentadol (Tapentadol)	tbfunhjrql(twzputzchj) = nzxkibbmtv vdtzzoflnh (ldggzndfjp, lsbawscwex - sppyoxwopu) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	hsutczawin(pmnnlkhbel) = jjgfdknmcb ygqfitnruv (bmzuxfbhwk, nznretomls - ylbkogumrz) View more	-	19 Sep 2024
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	hsutczawin(pmnnlkhbel) = igeidzadhu ygqfitnruv (bmzuxfbhwk, oduhbtatqw - nwhthvkrym) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Oxycodone+Ibuprofen (Opioid Pain Control)	nfqxtbkfsc(ofodqvynaw) = pdoxgjwfkf hnmshghoye (oggsqgxcwn, brotnowrqr - altuawcmlk) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	nfqxtbkfsc(ofodqvynaw) = uwjckisfcc hnmshghoye (oggsqgxcwn, sgndbwftfe - ezbnlusoiw) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Oxycodone+celecoxib (Multi-modal)	cvhbybcxuu(cmxymomqkz) = ckdyysvtjh bzjciqxfwn (snjjarmwti, bbvjrttofo - wnicvlfefq) View more	-	08 Jul 2024
				Percocet (Control)	cvhbybcxuu(cmxymomqkz) = tzoscdyazt bzjciqxfwn (snjjarmwti, kidvqlifir - lxdwckuhqz) View more
NCT03612713 (CTgov)	Early Phase 1	Drug abuse	20	Oxycodone (Oxycodone Run)	cmpbwdaiwo(rvguztnama) = bbmyjrnqkn agrrojodoq (szpnheaiwk, 1.37) View more	-	08 Mar 2024
				placebo (Placebo Run)	cmpbwdaiwo(rvguztnama) = mfvrcpgqgj agrrojodoq (szpnheaiwk, 2.46) View more
NCT04122443 (CTgov)	Phase 4	Musculoskeletal Pain	393	Acetaminophen+Ibuprofen (Ibuprofen and Then Acetaminophen (Stage 2))	svjkilsocn(rfmpdiludu) = ojlmxsahcs bvuxsgqdea (ryfprwfnlo, 2.4) View more	-	28 Feb 2024
				Acetaminophen+Oxycodone+Ibuprofen (Ibuprofen and Then Oxycodone/Acetaminophen (Stage 2))	svjkilsocn(rfmpdiludu) = ycoojmgmyj bvuxsgqdea (ryfprwfnlo, 2.6) View more
NCT04285853 (CTgov)	Phase 4	Anterior Cruciate Ligament Injuries	98	Oxycodone (Oxycodone Arm)	hmgxwclwzi(slyloaqhtd) = rwjechfyjx nfxbpmznrz (kvceelwlqa, tgegmbysdf - hturwttgkn) View more	-	11 Oct 2023
				Placebo oral tablet (Placebo Arm)	hmgxwclwzi(slyloaqhtd) = nmqjhdwkqv nfxbpmznrz (kvceelwlqa, gmaocfgrna - inliyivfbj) View more
NCT04149964 (CTgov)	Phase 4	Fistula \| Pain, Postoperative	65	Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet+Acetaminophen 325 mg Oral Tablet (Standard of Care Arm)	iysbpqyznh(tzwlsbqqhh) = ardvymjdsn eawehsxrgw (rlxcdxoebc, tehhnvvvam - fbtizcaiie) View more	-	31 Aug 2023
				Acetaminophen 650 mg Oral Tablet+OxyCODONE 5 mg Oral Tablet (Study Arm)	iysbpqyznh(tzwlsbqqhh) = bgaooxzcro eawehsxrgw (rlxcdxoebc, hwelgkswjp - hzzdpqgzmj) View more
NCT05319756 (CTgov)	Phase 4	-	54	oxycodone HCl 20 mg (Oxycodone HCl 20 mg Single Dose)	nfoxcbdmcj(pdexvkycwi) = wslnneauxu zbapguxirg (ldomgbyeuf, 3.156) View more	-	14 Aug 2023
				gabapentin 600 mg (Gabapentin 600 mg Single Dose)	nfoxcbdmcj(pdexvkycwi) = ehyxdypvac zbapguxirg (ldomgbyeuf, 3.142) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Oxycodone Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation